AU2013203262B2 - Humanized anti-CXCR5 antibodies, derivatives thereof and their uses - Google Patents
Humanized anti-CXCR5 antibodies, derivatives thereof and their uses Download PDFInfo
- Publication number
- AU2013203262B2 AU2013203262B2 AU2013203262A AU2013203262A AU2013203262B2 AU 2013203262 B2 AU2013203262 B2 AU 2013203262B2 AU 2013203262 A AU2013203262 A AU 2013203262A AU 2013203262 A AU2013203262 A AU 2013203262A AU 2013203262 B2 AU2013203262 B2 AU 2013203262B2
- Authority
- AU
- Australia
- Prior art keywords
- antibody
- fragment
- seq
- amino acid
- cxcr5
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 101000922405 Homo sapiens C-X-C chemokine receptor type 5 Proteins 0.000 claims abstract description 37
- 102100031658 C-X-C chemokine receptor type 5 Human genes 0.000 claims abstract description 31
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 18
- 201000010099 disease Diseases 0.000 claims abstract description 9
- 208000035475 disorder Diseases 0.000 claims abstract description 9
- 239000012634 fragment Substances 0.000 claims description 58
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 48
- 210000004027 cell Anatomy 0.000 claims description 28
- 238000000034 method Methods 0.000 claims description 22
- 208000004736 B-Cell Leukemia Diseases 0.000 claims description 8
- 206010005003 Bladder cancer Diseases 0.000 claims description 8
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 8
- 206010009944 Colon cancer Diseases 0.000 claims description 8
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 8
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims description 8
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims description 8
- 208000000389 T-cell leukemia Diseases 0.000 claims description 8
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 claims description 8
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 8
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 8
- 208000037976 chronic inflammation Diseases 0.000 claims description 8
- 208000037893 chronic inflammatory disorder Diseases 0.000 claims description 8
- 208000029742 colonic neoplasm Diseases 0.000 claims description 8
- 206010025135 lupus erythematosus Diseases 0.000 claims description 8
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 8
- 201000006417 multiple sclerosis Diseases 0.000 claims description 8
- 206010028417 myasthenia gravis Diseases 0.000 claims description 8
- 201000002528 pancreatic cancer Diseases 0.000 claims description 8
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 8
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 8
- 208000011580 syndromic disease Diseases 0.000 claims description 8
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 8
- 102000049118 human CXCR5 Human genes 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 150000007523 nucleic acids Chemical class 0.000 claims description 6
- 102000039446 nucleic acids Human genes 0.000 claims description 6
- 108020004707 nucleic acids Proteins 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 102100025277 C-X-C motif chemokine 13 Human genes 0.000 claims description 4
- 101000858064 Homo sapiens C-X-C motif chemokine 13 Proteins 0.000 claims description 4
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 4
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
Landscapes
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
The present invention relates to humanized antibodies that specifically bind to CXCR5 and can, for example, inhibit CXCR5 function. The invention also includes uses of the antibodies to treat or prevent CXCR5 related diseases or disorders.
Description
THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS: 1. An isolated antibody or fragment thereof that competitively inhibits the binding of an anti-CXCR5 antibody or fragment thereof to the extracellular domain of human CXCR5, wherein the anti-CXCR5 antibody or fragment thereof comprises: (a) a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 11, and a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 12; (b) the amino acid sequences of RSSKSLLHSSGKTYLY, RMSNLAS, MQHLEYPYT, GFSLIDYGVN, VIWGDGTTY, and IVY: (c) a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 13, SEQ ID NO: 14, or SEQ ID NO: 15, and a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 16; (d) the amino acid sequences of RSSKSLLHSSGKTYLY, RLSNLAS, MQHLEYPYT, GFSLIDYGVN, VIWGDGTTY, and IVY; (e) the amino acid sequences of RSSKSLLHSSGKTYLY, RLSSNLAS, MQHLEYPYT, GFSLIDYGVN, VIWGDGTTY, and IVY; (f) a variable light chain (VL) comprising the amino acid sequence of SEQ ID NO: 17, SEQ ID NO: 19, or SEQ ID NO: 21, and a variable heavy chain (Vh) comprising the amino acid sequence of SEQ ID NO: 23; (g) a variable light chain comprising the amino acid sequence of SEQ ID NO: 30, SEQ ID NO: 31, or SEQ ID NO: 32, and a variable heavy chain comprising the amino acid sequence of SEQ ID NO: 33 or SEQ ID NO: 34; (h) the amino acid sequences of RSSKSLLHSSGKTYLY, RMSNLA, MQHLEYPYT, GFSLIDYGVN, VIWGDGTTY, and IVY; (i) the amino acid sequences of RSSKSLLHSSGKTYLY, RLSNLA, MQHLEYPYT, GFSLIDYGVN, VIWGDGTTY, and IVY; (j) the amino acid sequences of RSSKSLLHSSGKTYLY, RLSSLA, MQHLEYPYT, GFSLIDYGVN, VIWGDGTTY, and IVY; (k) a variable light chain comprising the amino acid sequence of SEQ ID NO: 35, and a variable heavy chain comprising the amino acid sequence of SEQ ID NO: 37; (l) a variable light chain comprising the amino acid sequence of SEQ ID NO: 39, SEQ ID NO: 41, or SEQ ID NO: 43, and a variable heavy chain comprising the amino acid sequence of SEQ ID NO: 45 or SEQ ID NO: 47; (m) a variable light chain comprising the amino acid sequence of SEQ ID NO: 55, and a variable heavy chain comprising the amino acid sequence of SEQ ID NO: 56 or SEQ ID NO: 57; or (n) the amino acid sequences of RSSKSLLHSSGKTYLYW, RMSNLA, MQHLEYPYT, GFSLIDYGVN, VIWGDGTTY, and IVY; wherein the antibody or fragment thereof has a Kd less than 2.16 x 10"11 M. 2. An isolated antibody or fragment thereof that competitively inhibits the binding of an anti-CXCR5 antibody or fragment thereof to the extracellular domain of human CXCR5, wherein the anti-CXCR5 antibody or fragment thereof comprises a variable light chain comprising the amino acid sequence of SEQ ID NO: 32, and a variable heavy chain comprising the amino acid sequence of SEQ ID NO: 33, wherein the antibody or fragment thereof has a KD less than 2.16 x 10'11 M. 3. An isolated antibody or fragment thereof that competitively inhibits the binding of an anti-CXCR5 antibody or fragment thereof to the extracellular domain of human CXCR5, wherein the anti-CXCR5 antibody or fragment thereof comprises the amino acid sequences of RSSKSLLHSSGKTYLY, RLSSLA, MQHLEYPYT, GFSLIDYGVN, VIWGDGTTY, and IVY, wherein the antibody or fragment thereof has a KD less than 2.16 x 10"11 M. 4. The antibody or fragment thereof of any one of claims 1-3, wherein the antibody or fragment thereof further comprises one or more constant region domains. 5. The antibody or fragment thereof of any one of claims 1-3, wherein the antibody or fragment thereof further comprises a CHI, CH2, CH3, CL, or combinations thereof. 6. The antibody or fragment thereof of claim 4, wherein the one or more constant region domains are from an IgG antibody. 7. The antibody or fragment thereof of claim 6, wherein the IgG antibody is an IgG4 antibody. 8. The antibody or fragment thereof of any one of claims 1-3, wherein the antibody or fragment thereof is a single chain Fv antibody. 9. A pharmaceutical composition comprising a therapeutically effective amount of the antibody or fragment thereof of any one of claims 1-8 and a pharmaceutically acceptable carrier. 10. An isolated nucleic acid molecule encoding the antibody or fragment thereof of any one of claims 1-8. 11. A vector comprising the nucleic acid molecule of claim 10. 12. An isolated host cell comprising the vector of claim 11, excluding cells capable of generating a human being. 13. A method of treating a patient having a CXCR5 disease or condition, the method comprising administering to the patient a therapeutically effective amount of the antibody or fragment thereof of any one of claims 1-8 or of a pharmaceutical composition of claim 9. 14. The method of claim 13, wherein the CXCR5 disease or condition is selected from the group consisting of pancreatic cancer, colon cancer, bladder cancer, T cell leukemia, B cell leukemia, lupus, Sjoren's Syndrome, myasthenia gravis, multiple sclerosis, ulcerative colitis, rheumatoid arthritis, psoriatic arthritis, a chronic inflammatory disease, and a graft undergoing rejection. 15. A method of treating a patient having a disorder comprising CXCR5 positive cells, the method comprising administering to the patient a therapeutically effective amount of the antibody or fragment thereof of any one of claims 1-8 or of a pharmaceutical composition of claim 9. 16. The method of claim 15, wherein the disorder comprising CXCR5 positive cells is selected from the group consisting of pancreatic cancer, colon cancer, bladder cancer, T cell leukemia, B cell leukemia, lupus, Sjoren's Syndrome, myasthenia gravis, multiple sclerosis, ulcerative colitis, rheumatoid arthritis, psoriatic arthritis, a chronic inflammatory disease, and a graft undergoing rejection. 17. The method of claim 15, wherein at least one of the CXCR5 positive cells is a B cell. 18. The method of claim 15, wherein at least one of the CXCR5 positive cells is activated by CXCL13. 19. The method of claim 15, wherein at least one of the CXCR5 positive cells is a T cell. 20. The use of the antibody or fragment thereof of any one of claims 1-8 in the manufacture of a medicament for the treatment of a CXCR5 disease or condition in a patient. 21. The use according to claim 20, wherein the CXCR5 disease or condition is selected from the group consisting of pancreatic cancer, colon cancer, bladder cancer, T cell leukemia, B cell leukemia, lupus, Sjoren's Syndrome, myasthenia gravis, multiple sclerosis, ulcerative colitis, rheumatoid arthritis, psoriatic arthritis, a chronic inflammatory disease, and a graft undergoing rejection. 22. The use of the antibody or fragment thereof of any one of claims 1-8 in the manufacture of a medicament for the treatment of a disorder comprising CXCR5 positive cells. 23. The use according to claim 22, wherein the disorder comprising CXCR5 positive cells is selected from the group consisting of pancreatic cancer, colon cancer, bladder cancer, T cell leukemia, B cell leukemia, lupus, Sjoren's Syndrome, myasthenia gravis, multiple sclerosis, ulcerative colitis, rheumatoid arthritis, psoriatic arthritis, a chronic inflammatory disease, and a graft undergoing rejection. 24. The use according to claim 22, wherein at least one of the CXCR5 positive cells is a B cell. 25. The use according to claim 22, wherein at least one of the CXCR5 positive cells is activated by CXCL13. 26. The use according to claim 22, wherein at least one of the CXCR5 positive cells is a T cell. 27. A method of manufacturing the antibody or fragment thereof of any one of claims 1-8, the method comprising expressing the vector of claim 11 in a suitable host cell. 28. A kit comprising the antibody or fragment thereof of any one of claims 1-8 and instructions for use. 29. The antibody or fragment thereof according to any one of claims 1-8, the composition according to claim 9, the isolated nucleic acid according to claim 10, the vector according to claim 11, the isolated host cell according to claim 12, the method according to any one of claims 13 to 19 or 27, the use according to any one of claims 20 to 26, or the kit according to claim 28, substantially as hereinbefore described.
SANOFI
WATERMARK PATENT AND TRADE MARKS ATTORNEYS P32965AU02
Claims (29)
- THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS:1. An isolated antibody or fragment thereof that competitively inhibits the binding of an anti-CXCR5 antibody or fragment thereof to the extracellular domain of human CXCR5, wherein the anti-CXCR5 antibody or fragment thereof comprises: (a) a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 11, and a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 12; (b) the amino acid sequences of RSSKSLLHSSGKTYLY, RMSNLAS, MQHLEYPYT, GFSLIDYGVN, VIWGDGTTY, and IVY: (c) a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 13, SEQ ID NO: 14, or SEQ ID NO: 15, and a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 16; (d) the amino acid sequences of RSSKSLLHSSGKTYLY, RLSNLAS, MQHLEYPYT, GFSLIDYGVN, VIWGDGTTY, and IVY; (e) the amino acid sequences of RSSKSLLHSSGKTYLY, RLSSNLAS, MQHLEYPYT, GFSLIDYGVN, VIWGDGTTY, and IVY; (f) a variable light chain (VL) comprising the amino acid sequence of SEQ ID NO: 17, SEQ ID NO: 19, or SEQ ID NO: 21, and a variable heavy chain (Vh) comprising the amino acid sequence of SEQ ID NO: 23; (g) a variable light chain comprising the amino acid sequence of SEQ ID NO: 30, SEQ ID NO: 31, or SEQ ID NO: 32, and a variable heavy chain comprising the amino acid sequence of SEQ ID NO: 33 or SEQ ID NO: 34; (h) the amino acid sequences of RSSKSLLHSSGKTYLY, RMSNLA, MQHLEYPYT, GFSLIDYGVN, VIWGDGTTY, and IVY; (i) the amino acid sequences of RSSKSLLHSSGKTYLY, RLSNLA, MQHLEYPYT, GFSLIDYGVN, VIWGDGTTY, and IVY; (j) the amino acid sequences of RSSKSLLHSSGKTYLY, RLSSLA, MQHLEYPYT, GFSLIDYGVN, VIWGDGTTY, and IVY; (k) a variable light chain comprising the amino acid sequence of SEQ ID NO: 35, and a variable heavy chain comprising the amino acid sequence of SEQ ID NO: 37; (l) a variable light chain comprising the amino acid sequence of SEQ ID NO: 39, SEQ ID NO: 41, or SEQ ID NO: 43, and a variable heavy chain comprising the amino acid sequence of SEQ ID NO: 45 or SEQ ID NO: 47; (m) a variable light chain comprising the amino acid sequence of SEQ ID NO: 55, and a variable heavy chain comprising the amino acid sequence of SEQ ID NO: 56 or SEQ ID NO: 57; or (n) the amino acid sequences of RSSKSLLHSSGKTYLYW, RMSNLA, MQHLEYPYT, GFSLIDYGVN, VIWGDGTTY, and IVY; wherein the antibody or fragment thereof has a Kd less than 2.16 x 10"11 M.
- 2. An isolated antibody or fragment thereof that competitively inhibits the binding of an anti-CXCR5 antibody or fragment thereof to the extracellular domain of human CXCR5, wherein the anti-CXCR5 antibody or fragment thereof comprises a variable light chain comprising the amino acid sequence of SEQ ID NO: 32, and a variable heavy chain comprising the amino acid sequence of SEQ ID NO: 33, wherein the antibody or fragment thereof has a KD less than 2.16 x 10'11 M.
- 3. An isolated antibody or fragment thereof that competitively inhibits the binding of an anti-CXCR5 antibody or fragment thereof to the extracellular domain of human CXCR5, wherein the anti-CXCR5 antibody or fragment thereof comprises the amino acid sequences of RSSKSLLHSSGKTYLY, RLSSLA, MQHLEYPYT, GFSLIDYGVN, VIWGDGTTY, and IVY, wherein the antibody or fragment thereof has a KD less than 2.16 x 10"11 M.
- 4. The antibody or fragment thereof of any one of claims 1-3, wherein the antibody or fragment thereof further comprises one or more constant region domains.
- 5. The antibody or fragment thereof of any one of claims 1-3, wherein the antibody or fragment thereof further comprises a CHI, CH2, CH3, CL, or combinations thereof.
- 6. The antibody or fragment thereof of claim 4, wherein the one or more constant region domains are from an IgG antibody.
- 7. The antibody or fragment thereof of claim 6, wherein the IgG antibody is an IgG4 antibody.
- 8. The antibody or fragment thereof of any one of claims 1-3, wherein the antibody or fragment thereof is a single chain Fv antibody.
- 9. A pharmaceutical composition comprising a therapeutically effective amount of the antibody or fragment thereof of any one of claims 1-8 and a pharmaceutically acceptable carrier.
- 10. An isolated nucleic acid molecule encoding the antibody or fragment thereof of any one of claims 1-8.
- 11. A vector comprising the nucleic acid molecule of claim 10.
- 12. An isolated host cell comprising the vector of claim 11, excluding cells capable of generating a human being.
- 13. A method of treating a patient having a CXCR5 disease or condition, the method comprising administering to the patient a therapeutically effective amount of the antibody or fragment thereof of any one of claims 1-8 or of a pharmaceutical composition of claim 9.
- 14. The method of claim 13, wherein the CXCR5 disease or condition is selected from the group consisting of pancreatic cancer, colon cancer, bladder cancer, T cell leukemia, B cell leukemia, lupus, Sjoren's Syndrome, myasthenia gravis, multiple sclerosis, ulcerative colitis, rheumatoid arthritis, psoriatic arthritis, a chronic inflammatory disease, and a graft undergoing rejection.
- 15. A method of treating a patient having a disorder comprising CXCR5 positive cells, the method comprising administering to the patient a therapeutically effective amount of the antibody or fragment thereof of any one of claims 1-8 or of a pharmaceutical composition of claim 9.
- 16. The method of claim 15, wherein the disorder comprising CXCR5 positive cells is selected from the group consisting of pancreatic cancer, colon cancer, bladder cancer, T cell leukemia, B cell leukemia, lupus, Sjoren's Syndrome, myasthenia gravis, multiple sclerosis, ulcerative colitis, rheumatoid arthritis, psoriatic arthritis, a chronic inflammatory disease, and a graft undergoing rejection.
- 17. The method of claim 15, wherein at least one of the CXCR5 positive cells is a B cell.
- 18. The method of claim 15, wherein at least one of the CXCR5 positive cells is activated by CXCL13.
- 19. The method of claim 15, wherein at least one of the CXCR5 positive cells is a T cell.
- 20. The use of the antibody or fragment thereof of any one of claims 1-8 in the manufacture of a medicament for the treatment of a CXCR5 disease or condition in a patient.
- 21. The use according to claim 20, wherein the CXCR5 disease or condition is selected from the group consisting of pancreatic cancer, colon cancer, bladder cancer, T cell leukemia, B cell leukemia, lupus, Sjoren's Syndrome, myasthenia gravis, multiple sclerosis, ulcerative colitis, rheumatoid arthritis, psoriatic arthritis, a chronic inflammatory disease, and a graft undergoing rejection.
- 22. The use of the antibody or fragment thereof of any one of claims 1-8 in the manufacture of a medicament for the treatment of a disorder comprising CXCR5 positive cells.
- 23. The use according to claim 22, wherein the disorder comprising CXCR5 positive cells is selected from the group consisting of pancreatic cancer, colon cancer, bladder cancer, T cell leukemia, B cell leukemia, lupus, Sjoren's Syndrome, myasthenia gravis, multiple sclerosis, ulcerative colitis, rheumatoid arthritis, psoriatic arthritis, a chronic inflammatory disease, and a graft undergoing rejection.
- 24. The use according to claim 22, wherein at least one of the CXCR5 positive cells is a B cell.
- 25. The use according to claim 22, wherein at least one of the CXCR5 positive cells is activated by CXCL13.
- 26. The use according to claim 22, wherein at least one of the CXCR5 positive cells is a T cell.
- 27. A method of manufacturing the antibody or fragment thereof of any one of claims 1-8, the method comprising expressing the vector of claim 11 in a suitable host cell.
- 28. A kit comprising the antibody or fragment thereof of any one of claims 1-8 and instructions for use.
- 29. The antibody or fragment thereof according to any one of claims 1-8, the composition according to claim 9, the isolated nucleic acid according to claim 10, the vector according to claim 11, the isolated host cell according to claim 12, the method according to any one of claims 13 to 19 or 27, the use according to any one of claims 20 to 26, or the kit according to claim 28, substantially as hereinbefore described. SANOFI WATERMARK PATENT AND TRADE MARKS ATTORNEYS P32965AU02
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2013203262A AU2013203262B2 (en) | 2007-08-29 | 2013-04-09 | Humanized anti-CXCR5 antibodies, derivatives thereof and their uses |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US60/968,792 | 2007-08-29 | ||
| AU2008296538A AU2008296538B2 (en) | 2007-08-29 | 2008-08-27 | Humanized anti-CXCR5 antibodies, derivatives thereof and their uses |
| AU2013203262A AU2013203262B2 (en) | 2007-08-29 | 2013-04-09 | Humanized anti-CXCR5 antibodies, derivatives thereof and their uses |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2008296538A Division AU2008296538B2 (en) | 2007-08-29 | 2008-08-27 | Humanized anti-CXCR5 antibodies, derivatives thereof and their uses |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2013203262A1 AU2013203262A1 (en) | 2013-05-02 |
| AU2013203262B2 true AU2013203262B2 (en) | 2016-07-07 |
Family
ID=48444693
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2013203261A Active AU2013203261B2 (en) | 2007-08-29 | 2013-04-09 | Humanized anti-cxcr5 antibodies, derivatives thereof and their use |
| AU2013203265A Active AU2013203265B2 (en) | 2007-08-29 | 2013-04-09 | Humanized anti-CXCR5 antibodies, derivatives thereof and their uses |
| AU2013203264A Active AU2013203264B2 (en) | 2007-08-29 | 2013-04-09 | Humanized anti-CXCR5 antibodies, derivatives thereof and their uses |
| AU2013203262A Active AU2013203262B2 (en) | 2007-08-29 | 2013-04-09 | Humanized anti-CXCR5 antibodies, derivatives thereof and their uses |
Family Applications Before (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2013203261A Active AU2013203261B2 (en) | 2007-08-29 | 2013-04-09 | Humanized anti-cxcr5 antibodies, derivatives thereof and their use |
| AU2013203265A Active AU2013203265B2 (en) | 2007-08-29 | 2013-04-09 | Humanized anti-CXCR5 antibodies, derivatives thereof and their uses |
| AU2013203264A Active AU2013203264B2 (en) | 2007-08-29 | 2013-04-09 | Humanized anti-CXCR5 antibodies, derivatives thereof and their uses |
Country Status (1)
| Country | Link |
|---|---|
| AU (4) | AU2013203261B2 (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050276812A1 (en) * | 2004-06-01 | 2005-12-15 | Genentech, Inc. | Antibody-drug conjugates and methods |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4124480B2 (en) * | 1991-06-14 | 2008-07-23 | ジェネンテック・インコーポレーテッド | Immunoglobulin variants |
| AU770952B2 (en) * | 1999-03-01 | 2004-03-11 | Genentech Inc. | Antibodies for cancer therapy and diagnosis |
-
2013
- 2013-04-09 AU AU2013203261A patent/AU2013203261B2/en active Active
- 2013-04-09 AU AU2013203265A patent/AU2013203265B2/en active Active
- 2013-04-09 AU AU2013203264A patent/AU2013203264B2/en active Active
- 2013-04-09 AU AU2013203262A patent/AU2013203262B2/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050276812A1 (en) * | 2004-06-01 | 2005-12-15 | Genentech, Inc. | Antibody-drug conjugates and methods |
Non-Patent Citations (1)
| Title |
|---|
| SCHMUTZ, C., et al., "Chemokine receptors in the rheumatoid synovium: upregulation of CXCR5," Arthritis Research & Therapy, 2005, Vol. 7, No. 2, pages R217-R229. * |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2013203261B2 (en) | 2016-07-14 |
| AU2013203265A1 (en) | 2013-05-02 |
| AU2013203265B2 (en) | 2016-06-23 |
| AU2013203264A1 (en) | 2013-05-02 |
| AU2013203261A1 (en) | 2013-05-02 |
| AU2013203264B2 (en) | 2016-07-07 |
| AU2013203262A1 (en) | 2013-05-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230416374A1 (en) | Selective elimination of erosive cells | |
| ES2912651T3 (en) | Anti-CD137 antibodies | |
| JP2009502171A5 (en) | ||
| KR102321372B1 (en) | Antibodies to interleukin-6 and uses thereof | |
| SI2195023T1 (en) | Humanized anti-cxcr5 antibodies, derivatives thereof and their uses | |
| US9631024B2 (en) | Antibodies that bind LGR4, their use in inhibiting neoplastic cells and in treating tumors | |
| JP2013537418A5 (en) | ||
| CA2901468C (en) | Pan-elr+ cxc chemokine antibodies | |
| EP3976652A1 (en) | Tigit and pd-1/tigit-binding molecules | |
| AU2012268939A1 (en) | Selective elimination of erosive cells | |
| US10556947B2 (en) | Binding molecule that binds specifically to the precursor of brain-derived neurotrophic factor | |
| WO2020161478A1 (en) | ANTIBODIES AGAINST hEPCR | |
| CN117860786B (en) | Pharmaceutical and diagnostic use of genetically modified mesenchymal stem cells in a variety of diseases | |
| EP4155322A1 (en) | Anti-trka antibody or antigen-binding fragment thereof, preparation method therefor, and application thereof | |
| EP3768712A1 (en) | Anti-cd137 antibodies for combination with anti-pd-1 antibodies | |
| EP2663329A2 (en) | Tlr3 binding agents | |
| AU2013203262B2 (en) | Humanized anti-CXCR5 antibodies, derivatives thereof and their uses | |
| KR20150027048A (en) | Combination therapy of anti-mif antibodies and chemotherapeutics | |
| JPWO2020237173A5 (en) | ||
| TWI825131B (en) | Treatment or preventive agents for HTLV-1 associated myelopathy (HAM), and treatment methods for HAM | |
| WO2014036384A1 (en) | Use of il-20 antagonists for promoting bone fracture healing | |
| WO2024022462A1 (en) | Anti-ilt4 single-domain antibody and use thereof | |
| EP3374393A2 (en) | Anti-human il-3 antibodies, their use in treatment of a disease or malfunction associated with elevated expression or levels of il-3, and their use in a method to detect human il-3 | |
| EP3904383A1 (en) | Anti-ox40 monoclonal antibody and application thereof | |
| CN113817058A (en) | Anti-human IL-17RC monoclonal antibody and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) |